Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-03-22
2005-03-22
Horlick, Kenneth R. (Department: 1637)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S091200, C435S325000, C536S023100, C536S024300, C536S024320, C536S024330
Reexamination Certificate
active
06869766
ABSTRACT:
This invention pertains to the identification and isolation of a gene implicated in the fatty liver dystrophy (fld) phenotype. Mouse and human forms of the novel gene, designated herein as Lpin1/LPIN1 (mouse and human genes, respectively), are identified. This invention additionally provides methods of screening for agents that alter adipose tissue development. The methods involve contacting a cell containing a Lpin1 gene with a test agent; and detecting a change in the expression or activity of a Lpin1 gene product, where a difference in the expression or activity of Lpin1 in the contacted cell indicates that the agent alters or is likely to alter adipose tissue development. Also provided are methods of identifying Lpin1 mutations, and methods of mitigating symptoms of lipodystrophy, obesity, diabetes, atherosclerosis and related pathologies.
REFERENCES:
patent: 5476926 (1995-12-01), Speigelman et al.
patent: 5698389 (1997-12-01), de la Brousse et al.
patent: 5723115 (1998-03-01), Serrero
patent: 5756467 (1998-05-01), Kagawa et al.
patent: 5776906 (1998-07-01), Sekiya
patent: 5827740 (1998-10-01), Pittenger
patent: 5855917 (1999-01-01), Cook et al.
patent: 5935810 (1999-08-01), Freidman et al.
patent: 6232066 (2001-05-01), Felder et al.
patent: WO 9314109 (1993-07-01), None
patent: WO 9929725 (1999-06-01), None
patent: WO 9945135 (1999-09-01), None
patent: WO 9951740 (1999-10-01), None
patent: WO 0028444 (2000-05-01), None
Klingenspor et al. Altered Gene expression pattern in the fatty liver dystrophy mouse reveals impaired insulin-mediated cytoskeleton dynamics. vol. 274, No. 33, pp. 23078-23084, Aug. 1999.*
Ailhaud et al. (1992) “Cellular and Molecular Aspects of Adipose Tissue Development”Ann. Rev. Nutr. 12: 207-233.
Cao and Hegele (2000) “Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy”Hum. Mol. Genet. 9: 109-112.
Comuzzie et al. (1997) “A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2”Nature Genet. 15: 273-275.
Dörfler et al. (1993) “Lipoatrophic diabetes”Clin. Investig. 71: 264-269.
Garg (2000) “Gender Differences in the Prevalence of Metabolic Complications in Familiar Partial Lipodystrophy (Dunnigan Variety)”J. Clin. Endocrinol. Metab. 85: 1776-1782.
Hager et al. (1998) “A genome-wide scan for human obesity genes reveals a major susceptibility locus on chromosome 10”Nature Genet. 20: 304-308.
Klingenspor et al., (1999) “Altered Gene Expression Pattern in the Fatty Liver Dystrophy Mouse Reveals Impaired Insulin-mediated Cytoskeleton Dynamics”J. Biol. Chem. 274: 23078-23084.
Langner et al. (1989) “The Fatty Liver Dystophy (fld) Mutation”J. Biol. Chem. 264: 7994-8003.
Langner et al. (1991) “Characterization of the Peripheral Neuropathy in Neonatal and Adult Mice That Are Homozygous for the Fatty Liver Dystophy (fld) Mutation”J. Biol. Chem. 266: 11955-11964.
Péterfy et al. (1999) “Genetic, Physical, and Transcript Map of the fld Region on Mouse Chromosome 12”Genomics62: 436-444.
Rehnmark et al. (1998) “The fatty liver dystrophy mutant mouse: microvesicular steatosis associated with altered expression levels of peroxisome proliferator-regulated proteins”J. Lipid Res. 39: 2209-2217.
Rotimi et al. (1999) “The Quantitative Trait Locus on Chromosome 2 for Serum Leptin Levels Is Confirmed in African-Americans”Diabetes48: 643-644.
Seip and Trygstad (1996) “Generalized lipodystrophy, congenital and acquired (lipoatrophy)”Acta Paediatr. Scand. Suppl. 413: 2-28.
Senior and Gellis (1964) “The Syndromes of Total Lipodystrophy and of Partial Lipodystrophy”Pediatrics33: 593-612.
Shackleton et al. (2000) “LMNA, encoding lamin A/C, is mutated in partial lipodystophy”Nature Genet. 24: 153-156.
Shimomura et al. (1998) “Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy”Genes. Dev. 12: 3182-3194.
Shimomura et al. (1999) “Congenital generalized lipodystrophy (CGL) is a rate autosomal recessive disorder characterized by a paucity of adipose (fat) tissue which is evident at birth and . . . ”Nature401: 73-76.
Péterfy Miklós
Reue Karen
Quine I. D. Law Group, PC.
The Regents of the University of California
Wilder Cynthia
LandOfFree
Gene associated with regulation of adiposity and insulin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene associated with regulation of adiposity and insulin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene associated with regulation of adiposity and insulin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3428630